Aytu BioPharma Inc

NASDAQ:AYTU   4:00:00 PM EDT
0.21
0.00 (-2.32%)
7:31:26 PM EDT: $0.21 -0.01 (-2.61%)
Earnings Announcements

Aytu Biopharma QTRLY Net Revenue Of $27.7 Million Driven By 34% Growth In Rx Segment

Published: 11/14/2022 23:11 GMT
Aytu BioPharma Inc (AYTU) - Aytu Biopharma Inc- Qtrly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment.
Aytu Biopharma Inc- Qtrly Loss per Share $0.06.
Further Company Coverage: Aytuo ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $29.5 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $28 Million
Next Quarter EPS Guidance is expected to be -$0.05

More details on our Analysts Page.